Cervical cancer screening: From molecular basis to diagnostic practice, going through new technologies

Technology in Cancer Research and Treatment

Volumn 7, Issue 3, 2008, Pages 161-174

  Zappacosta, Roberta ^a   Rosini, Sandra ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cervical cancer; E6 E7 mRNA; HPV review; New technologies

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENE PRODUCT;

CANCER MORTALITY; CANCER SCREENING; CARCINOGENESIS; CYTOLOGY; DNA METHYLATION; DNA TEST; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC PROCEDURES; HEALTH HAZARD; HUMAN; IN SITU HYBRIDIZATION; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SOUTHERN BLOTTING; TECHNOLOGY; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS LOAD; VIRUS ONCOGENE; WART VIRUS;

EID: 45349098667     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460800700302     Document Type: Review

References (101)

1. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 (2005).
2. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M. J. Cancer statistics 2007. CA Cancer J Clin 57, 43-66 (2007).
3. Bray, F., Ferlay, J., Pisani, P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94, 153-156 (2001).
4. Cervix Cancer Screening. Lyons: International Agency for Research on Cancer (2005).
5. Arbyn, M., Raifu, A. O., Autier, P., Ferlay, J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 18, 1708-1715 (2007).
6. Stoler, M. H., Schiffman, M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285, 1500 (2001).
7. Sasieni, P. D., Cuzick, J., Lynch-Framery, E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 73, 1001-1005 (1996).
8. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon, France: World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 64 (1995).
9. Arbyn, M., Buntinx, F., Van Ranst, M., Paraskevaidis, E., Martin-Hirsch, P., Dillner, J. Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial Neoplasia. J Natl Cancer Inst 18, 280-287 (2004).
10. Cuzick, J. Role of HPV testing in clinical practice. Virus Res 89, 263-269 (2002).
11. Duarte-Franco, E., Franco, E. L. Cancer of the uterine cervix. BMC Women's Health 4 (suppl 1), S13 (2004).
12. Staler M. H., Schiffman M. Toward optimal laboratory use. Interobserver reproducibility of cervical cytology and hystologic interpretations. Realistic estimates from the ASCUS/LSIL Triage Study. JAMA 285, 1500-1505 (2001).
13. Renshaw, A. A., Davey, D. D., Birdsong, G. G., Walsh, M., Styer, P. E., Mody, D. R., Solomon, D. Precision in gynaecologic cytologic interpretation: a study from the College of American Pathologists Interlaboratory Comparison Program in ervicovaginal Cytology. Arch Pathos Lab Med 127, 1413-1420 (2003).
14. Confortini, M., Carozzi, F., Dalla Palma, P., Ghiringello, B., Parisio, F., Prandi, S., Ronco, G., Ciatto, S., Montanari, G. GISCI Working Group for Cervical Cytology. Interlaboratory reproducibility of atypical squamous cells of undetermined significance report: a national survey. Cytopathology 14, 263-268 (2003).
15. Cibas, E. S., Alonzo, T.A., Austin, R. M., Bolick, D. R., Glant, M. D., Henry, M. R., Moriarty, A. T., Molina, J. T., Rushing, L., Slowman, S. D., Torno, R.. Eisenhut, C. C. The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. Am J Clin Pathol 129, 193-201 (2008).
16. Abulafia, O., Pezzullo, J. C., Sherer, D. M. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol 90, 137-144 (2003).
17. Davey, E., Barratt, A., Irwing, L., Chan, S. F., Macaskill, P., Mannes, P., Saville, A. M. Effect of study design and quality on unsatisfactory rates, cytological classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367, 122-132 (2006).
18. Davey, E., d'Assuncao, J., Irwig, L., Macaskill, P., Chan, S. F., Richards, A., Farnsworth, A. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 335, 28-35 (2007).
19. Nance, K. V. Evolution of Pap testing at a community hospital - a ten years experience. Diagnostic Cytopathology 35, 148-153 (2007).
20. Papillo, J. L, St John, T. L., Leiman, G. Effectiveness of the ThinPrep Imaging System: clinical experience in a low risk screening population. Diagnostic Cytopathology 36, 155-160 (2008).
21. Bernstein, S. J., Sanchez-Ramos, L., Ndubisi, B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: A metaanalysis of prospective studies comparing cytologic diagnosis and sample adeguacy. Am J Obstet Gynecol 185, 308-317 (2001).
22. Klinkhamer, P. J. J. M., Meerding, W. J., Rosier, P. F. W. M., Hanselaar, A. G. J. M. Liquid based cervical cytology: a review of the literature with methods of evidence based medicine. Cancer 99, 263-271 (2003).
23. Moss, S. M., Gray, A., Legood, R., Henstock, E. First Report to the Department of Health on Evaluation of LBC. www.cancerscreening.nhs.uk/cervical/ lbc-pilot-evaluation.pdf (2002).
24. Snijders, P. J., Steenbergen, R. D., Heideman, D. A., Meijer, C. J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 208, 152-164 (2006).
25. Clifford, G. M., Gallus, S., Herrero, R. Worldwide distribution of human Papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV Prevalence Survey: a pooled analysis. Lancet 366, 991-998 (2005).
26. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., Shah, K. V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55, 244-265 (2002).
27. Baay, M. F., Smits, E., Tjalma, W. A. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women, Int J Cancer 108, 258-261 (2004).
28. Munoz, N., Mendez, F., Posso, H., Molano, M., Van den Brule, A., Ronderos, M., Meijer, C., Munoz, A., for the Instituto National de Cancerologia HPV Study Group. Incidence, duration and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190, 234-242 (2004).
29. Muñoz, N., Castellsague, X., de Gonzalez, A. B., Gissman, L. Chapter I: HPV in the etiology of human cancer. Vaccine 24 (Suppl 3), S1-S7 (2006).
30. Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., Franceschi, S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88, 63-73 (2003).
31. Kraus, I., Molden, T., Holm, R., Lie, A. K., Karlsen, F., Kristensen, G. B., Skomedal, H. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 44, 1310-1317 (2006).
32. De Sanjosé, S., Diaz, M., Castellsagué, X., Clifford, G., Bruni, L., Muñoz, N., Bosch, F. X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7, 453-459 (2007).
33. zur Hausen, H. Viruses in human cancers. Science 254, 1176-1273 (1991).
34. Solomon, D. Chapter 14: role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr 31, 97-106 (2003).
35. Smith, J. S., Lindsay, L., Hoots, B., Keys, J., Pranceschi, S., Winer, R. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121, 621-632 (2007).
36. Dillner, J. The serological response to Papillomavirus. Sem Cancer Biol 9, 423-430 (1999).
37. Hopman, A. H., Kamps, M. A., Smedts, F., Speel, E. J., Herrington, C. S., Ramaekers, F. C. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer 115, 419-428 (2005).
38. Caussy, D., Orr, W., Daya, A. D., Roth, P., Reeves, W., Rawls, W. Evaluation of methods for detection human Papillomavirus deoxiribonucleotide sequences in clinical specimens. J Clin Microbiol 26, 236-243 (1988).
39. Seedlacek, T. V. Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol 42, 206-220 (1999).
40. Van Doorn, L. J., Kleter, B., Quint, W. G. Molecular detection and genotyping of human papillomavirus. Expert Rev Mol Diagn 1, 394-402 (2001).
41. Boulet, G. A. V., Horvath, C. A. J., Berghmans, S., Bogersn, J. Cancer Epidemiol Biomarkers Prev 17, 810-817 (2008).
42. Perrons, C., Jelley, R., Kleter, B., Quint, W., Brink, N. Detection of persistent high risk human papillomavirus infection with Hybrid Capture II and specific SPF10/LiPA. J Clin Virol 32, 278-285 (2005).
43. Chan, P. K., Cheung, T. H., Tam, A. O., Lo, K. W., Yim, S. F., Yu, M. M., To, K. F., Wong, Y. F., Cheung, J. L., Chang, D. P., Hui, M., Ip, M. Biases in human Papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118, 243-245 (2006).
44. Monsonego, J., Bohbot, J. M., Pollini, G. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 99, 160-168 (2005).
45. Sandri, M. T., Lentati, P., Benini, E. Comparison of the Digene HC2 Assay and the Roche AMPLICOR human Papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 44, 2141-2146 (2006).
46. Kulusingam, S. L., Hughes, J. P., Kiviat, N. B., Mao, C., Weiss, N. S., Kuypers, J. M. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288, 1749-1757 (2002).
47. Shiftman, M., Wheeler, C., Dasgupta, A., Salomon, D., Castle, P. E., for the ALTS Group. A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol 124, 1-11 (2005).
48. Carozzi, F. M., Del Mistro, A., Confortini, M., Sani, C., Puliti, D., Trevisan, R. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting: intralaboratory and interlaboratory quality control in seven laboratories partecipating in the same clinical trial. Am J Clin Pathol 124, 1-6 (2005).
49. Cubie, H. A., Moore, C., Waller, M., Moss, S., on behalf of the National Cervical Screening Committee LBC/HPV Pilot Steering Group. The development of a quality assurance program for HPV testing with the UK NHS cervical screening LBC/HPV studies. J Clin Virol 33, 287-292 (2005).
50. Cuschieri, K. S., Whitley, M. J., Cubie, H. A. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 73, 65-70 (2004).
51. Belinson, J., Qiao, Y. L., Pretorius, R., Zhang, W. H., Elson, P., Li, L., Pan, Q. J., Pischer, C., Lorincz, A., Zahniser, D. Shanxi Province cervical cancer study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 83, 439-444 (2001).
52. Dalla Palma, P., Pojer, A., Girlando, S. HPV triage of women with atypical squamous cells of undetermined significance: a 3-year experience in an Italian organized program. Cytopathology 16, 22-27 (2005).
53. Walboomers, J. M., Jacobs, M. V., Manos, M. M. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19 (1999).
54. Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan D. C., Patel, S. S. Prevalence of HPV infection among females in the United States. J Am Med Assoc 297, 813-819 (2007).
55. Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348, 518-527 (2003).
56. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188, 1383-1387 (2003).
57. Solomon, D., Schiffman, M. H., Tarone, R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 93, 293-297 (2001).
58. Rodriguez, A. C., Shiffman, M., Herrero, R., Wacholder, S., Hidesteim, A., Castle, P. E., Solomon, D., Burk, R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100, 513-517 (2008).
59. Cuzick, J. Role of HPV testing in clinical practice. Virus Research 89, 263-269 (2002).
60. Cuschieri, K. S., Cubie, H. A. The role of Human Papillomavirus testing in cervical screening. J Clin Virol 32S, S34-S42 (2005).
61. Doorbar, J. The papillomavirus life cycle. J Clin Virol 32S: S7-S15 (2005).
62. Wentzensen, N., Vinokurova, S., von Knebel, D. M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer in the female lower genital tract. Cancer Res 64, 3878-3884 (2004).
63. Tang, S. M., Tao, J. P., McCoy Jr. Zheng, Z. M. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 80, 4249-4251 (2006).
64. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110, 525-541 (2006).
65. Lichtig, H., Algrisi, M., Botzer, L. E., Abadi, T., Verbitzky, Y., Jackman, A., Tommasino, M., Zehbe, I., Sherman, L. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350, 216-219 (2006).
66. Guess, J. C., McCance, D. J. Decreased Migration of Langerhans Precursor-Like Cells in Response to Human Keratinocytes Expressing Human Papillomavirus Type 16 E6/E7 Is Related to Reduced Macrophage Inflammatory Protein-3 Production. Virol 79, 14852-14857 (2005).
67. Biswas, S. K., Sodhi , A. Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved. Int J Immunopathol Pharmacol 15, 183-187 (2002).
68. Scott, M., Nakagawa, M., Moscicki, A. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8, 209-213 (2001).
69. Duensing, S., Munger, K.. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 109, 157-161 (2004).
70. Rosini, S., Zappacosta, R., Di Bonaventura, G., Caraceni, D., Pilla, D., Di Girolamo, G., Esposito, A., Orsini, T., Setta, S., Vizzino, M., Piccolomini, M., Piccolomini, R. Management and triage of women in follow-up for low-grade cervical disease: association of HPV-DNA and RNA-based methods. Int J Immunopathol Pharmacol 20, 341-347 (2007).
71. Molden, T., Nygård, J. F., Kraus, I., Karlsen, F., Nygård, M., Skare, G. B., Skomedal, H., Thoresen, S. Ø., Hagmar, B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 10, 973-977 (2005).
72. Kraus, I., Molden, T., Ernø, L. E., Skomedal, H., Karlsen, F., Hagmar, B. Human Papillomavirus oncogenic expression in the dysplastic portio: an investigation of biopsies from 190 cervical cones. Br J Cancer 5, 1407-1412 (2004).
73. Lilli, F. B. Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. Clin Infect Dis 40, 451-457 (2005).
74. Hernandez-Hernandez, D. M., Ornelas-Bernal, L., Guido-Jimenez, M., Presa-Garcia, T., Varado-Cabrero, I., Salcedo-Vargas, M., Mohar-Betancourt, A., Garcia-Carranca, A. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol 90, 310-317 (2003).
75. De Oer, M. A., Jordanova, E. S., Kenter, G. G., Peters, A. A., Corver, W. E., Trimbos, J. B., Fleuren, G. J. High Human Papillomavirus oncogene mRNA expression and not viral load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 13, 132-138 (2007).
76. Swan, D. C., Tucker, R. A., Tortolero-Luna, G., Mitchell, M. F., Wideroff, L., Unger, E. R., Nisenbaum, R. A., Reeves, W. C., Icenogle, J. P. Human papilloma (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 37, 1030-1034 (1999).
77. Zerbini, M., Venturosi, S., Cricca, M., Gallinella, G., De Simone, P., Costa, S., Santini, D., Musiani, M. Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J Clin Pathol 54, 377-380 (2001).
78. Esteller, M., Herman, J. G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196, 1-7 (2002).
79. Baylin, S. B., Herman, J. C. DNA hypermethylation intumorigenesis: epigenetic joins genetics. Trends Genet 16, 168-174 (2000).
80. Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413 (2002).
81. Steebergen, R. D., Kramer, D., Braakhuis, B. J., Stern, P. L. Verheijen R.H., Meijer C.J., Snijders P.J. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 96, 294-305 (2004).
82. Fenq, Q., Balasubramanian, A., Hawes, S. E., Tiure, P., Sow, P. S., Dem, A. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 97, 273-282 (2005).
83. Li, J., Zhang, Z., Bidder, M., Funk, M. C., Nguyen, L., Goodfellow, P. J., Rader, J. S. IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol 96, 150-158 (2005).
84. Gustafson, K. S., Furth, E. E., Heiyjan, D. F., Pansier, Z. B., Clark, D. P. DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis. Cancer 102, 259-268 (2004).
85. Wentzensen, N., von knebel Doeberitz, M. Biomarkers in cervical cancer screening. Dis Markers 23, 315-330 (2007).
86. INK4a expression in cervical premalignant and malignant lesions. Exp Mol Pathol 80, 192-196 (2006).
87. INK4a. Int J Oncol 29, 705-711 (2006).
88. INK4a and high-risk Human Papillomavirus. Acta Obstet Gynecol Scand 86, 94-98 (2007).
89. Wentzenses, N., Bergeron, C., Cas, F., Eschenbach, D., Vinokurova, S., von Knebel, D. M. Evalutation of a nuclear score for p16 INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 105, 461-467 (2005).
90. Wise-Draper, T. M., Wells, S. I. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci 1, 1003-1017 (2008).
91. Asadurian, Y., Kurilin, H., Lichtig, H., Jackman, A., Gonen, P., Tommasino, M., Zehbe, I., Sherman, L. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J Med Virol 79, 1751-1760 (2007).
92. Varnai, A. D., Bollmann, M., Bankfalvi, A., Speich, N., Schmitt, C., Griefingholt, H., Kovács, K., Klozoris, C., Bollmann, R. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Report 19, 457-465 (2008).
93. Molden, T., Kraus, I., Skomedal, H., NordstrØm, T., Karlsen, F. Pre-Tect™ HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Meth 142, 204-212 (2007).
94. Cuschieri, K. S., Beattie, G., Hassan, S., Robertson, K., Cubie, H. A. Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods 124: 211-215 (2005).
95. Nakagawa, S., Yoshikawa, H., Yasugi, T., Kimura, M., Kawana, K., Matsumoto, K., Yamada, M., Onda, T., Taketani, Y. Ubiquitous presence of E6 and E7 transcrips in human papillomavirus-positive cervical carcinoma regardless of its type. J Med Virol 62, 251-258 (2000)
96. Skomedal, H., Kraus, I., Silva, I., Molden, T., Hovland, S., Morland, G., Morland, E., Karlsen, F. Direct Detection of Cervical Carcinogenesis through mRNA, in Emerging issues on HPV infections: from science to practice, pp 82-102. Ed., Joseph Monsonego. Karger. Paris (2006).
97. Lie, A. K., Risberg, T. B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., Onsnid, M., Thoresen, S. DNA- versus RNA-based methods for human Papillomavirus detection in cervical neoplasia. Gynecol Oncol 97, 908-915 (2005).
98. Welters, M. J., Renter, G. G., Piersma, S. J., Vloon, A. P., Löwik, M. J., Berends-van der Meer, D. M., Drijfhout, J. W., Valentijn, A. R., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., Offringa, R., Melief, C. J., van der Burg, S. H. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. Clin Cancer Res 14, 178-187 (2008).
99. Schiller, J. T., Douglas, R. L. Perspectives on HPV virus-like particle Vaccine efficacy, in Emerging issues on HPV infections: from science to practice, pp 2217-226. Ed., Joseph Monsonego. Karger. Paris (2006).
100. Stanley, M., Lowy, D. R., Frazer, I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24, S106-S113 (2006).
101. Psyrri, A., Di Maio, D. Human papillomavirus in cervical and head-and neck cancer. Nature Clin Prac Oncol 5, 24-31 (2008).